tisagenlecleucel
novartis
['tisagenlecleucel', 'lymsm', 'lymphoma', 'elara', 'follicular']
results from the phase 2 elara trial show that tisagenlecleucel continued to induce high rates of durable responses in patients with relapsed/refractory follicular lymphoma after 2 years of follow-up. #lymsm #ash22 | 
Oncology news and insights from leading researchers and cancer centers.